Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

AUTL

Autolus Therapeutics (AUTL)

Autolus Therapeutics PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AUTL
FechaHoraFuenteTítuloSímboloCompañía
17/05/202407:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
17/05/202406:00GlobeNewswire Inc.Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
14/05/202409:00GlobeNewswire Inc.Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) CongressNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202408:33Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202406:00GlobeNewswire Inc.Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference CallNASDAQ:AUTLAutolus Therapeutics PLC
24/04/202409:00GlobeNewswire Inc.Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCONASDAQ:AUTLAutolus Therapeutics PLC
23/04/202406:00GlobeNewswire Inc.Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024NASDAQ:AUTLAutolus Therapeutics PLC
02/04/202406:00GlobeNewswire Inc.Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALLNASDAQ:AUTLAutolus Therapeutics PLC
01/04/202406:00GlobeNewswire Inc.Autolus Therapeutics Announces Changes to its Board of DirectorsNASDAQ:AUTLAutolus Therapeutics PLC
14/03/202406:00GlobeNewswire Inc.Autolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
12/03/202406:00GlobeNewswire Inc.Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing siteNASDAQ:AUTLAutolus Therapeutics PLC
11/03/202406:00GlobeNewswire Inc.Autolus Therapeutics announces publication in Blood Cancer JournalNASDAQ:AUTLAutolus Therapeutics PLC
29/02/202406:00GlobeNewswire Inc.Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024NASDAQ:AUTLAutolus Therapeutics PLC
23/02/202416:28Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AUTLAutolus Therapeutics PLC
22/02/202406:00GlobeNewswire Inc.Autolus Therapeutics announces publication in Nature Communications NASDAQ:AUTLAutolus Therapeutics PLC
21/02/202416:01Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AUTLAutolus Therapeutics PLC
14/02/202407:37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
09/02/202416:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AUTLAutolus Therapeutics PLC
08/02/202406:00GlobeNewswire Inc.Autolus Announces Pricing of Underwritten OfferingNASDAQ:AUTLAutolus Therapeutics PLC
08/02/202404:45GlobeNewswire Inc.BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs  NASDAQ:AUTLAutolus Therapeutics PLC
07/02/202421:00Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:AUTLAutolus Therapeutics PLC
23/01/202406:00GlobeNewswire Inc.Autolus Therapeutics announces publication in ACS Chemical BiologyNASDAQ:AUTLAutolus Therapeutics PLC
22/01/202406:54Dow Jones NewsAutolus Therapeutics Gets BLA Acceptance for Obecabtagene AutoleucelNASDAQ:AUTLAutolus Therapeutics PLC
22/01/202406:00GlobeNewswire Inc.Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)NASDAQ:AUTLAutolus Therapeutics PLC
10/01/202406:00GlobeNewswire Inc.Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of DirectorsNASDAQ:AUTLAutolus Therapeutics PLC
09/12/202319:30GlobeNewswire Inc.Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023NASDAQ:AUTLAutolus Therapeutics PLC
28/11/202313:59Dow Jones NewsCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNASDAQ:AUTLAutolus Therapeutics PLC
27/11/202306:54Dow Jones NewsAutolus Seeks FDA OK of Obe-Cel in Adult B-Cell Acute Lymphoblastic LeukemiaNASDAQ:AUTLAutolus Therapeutics PLC
27/11/202306:00GlobeNewswire Inc.Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)NASDAQ:AUTLAutolus Therapeutics PLC
15/11/202306:00GlobeNewswire Inc.Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023NASDAQ:AUTLAutolus Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:AUTL